JP2019515927A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515927A5
JP2019515927A5 JP2018556356A JP2018556356A JP2019515927A5 JP 2019515927 A5 JP2019515927 A5 JP 2019515927A5 JP 2018556356 A JP2018556356 A JP 2018556356A JP 2018556356 A JP2018556356 A JP 2018556356A JP 2019515927 A5 JP2019515927 A5 JP 2019515927A5
Authority
JP
Japan
Prior art keywords
infection
pharmaceutical composition
composition according
subject
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018556356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030236 external-priority patent/WO2017190070A1/en
Publication of JP2019515927A publication Critical patent/JP2019515927A/ja
Publication of JP2019515927A5 publication Critical patent/JP2019515927A5/ja
Pending legal-status Critical Current

Links

JP2018556356A 2016-04-29 2017-04-28 感染症の処置のための方法 Pending JP2019515927A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662329514P 2016-04-29 2016-04-29
US62/329,514 2016-04-29
US201662400503P 2016-09-27 2016-09-27
US62/400,503 2016-09-27
US201762470419P 2017-03-13 2017-03-13
US62/470,419 2017-03-13
PCT/US2017/030236 WO2017190070A1 (en) 2016-04-29 2017-04-28 Methods for the treatment of infection

Publications (2)

Publication Number Publication Date
JP2019515927A JP2019515927A (ja) 2019-06-13
JP2019515927A5 true JP2019515927A5 (enExample) 2020-06-18

Family

ID=60161141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556356A Pending JP2019515927A (ja) 2016-04-29 2017-04-28 感染症の処置のための方法

Country Status (7)

Country Link
US (2) US20190133995A1 (enExample)
EP (1) EP3448377A4 (enExample)
JP (1) JP2019515927A (enExample)
CN (1) CN109715152A (enExample)
AU (1) AU2017258765A1 (enExample)
CA (1) CA3022391A1 (enExample)
WO (1) WO2017190070A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019240212A1 (ja) * 2018-06-14 2019-12-19 株式会社カネカ 薬学的活性成分を含む製剤
WO2022204014A1 (en) * 2021-03-25 2022-09-29 Per Os Biosciences, Llc. Compositions and methods for treating coronavirus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
CN1939917A (zh) * 1999-03-22 2007-04-04 免疫力药品有限公司 大麻酯衍生物及其药用
US8586767B2 (en) * 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
ES2581212T3 (es) * 2005-11-07 2016-09-02 Murty Pharmaceuticals, Inc. Administración mejorada de tetahidrocannabinol
WO2009158499A2 (en) * 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
KR20160002709A (ko) * 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
US20150328198A1 (en) * 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Similar Documents

Publication Publication Date Title
Blanchette et al. Current therapies in treatment and prevention of fracture wound biofilms: why a multifaceted approach is essential for resolving persistent infections
RU2015132211A (ru) Способы лечения микробных инфекций, в том числе мастита
US20140371179A1 (en) Methods and Compositions for Treating Esophageal Diseases
JP2020524689A5 (enExample)
UA124661C2 (uk) Композиція, що містить антибіотик та диспергатор або антиадгезивний агент
US20220211801A1 (en) Compositions and methods for treating nail infections
AU2020232773B2 (en) Percutaneous anti-microbiota formulations
AU2013259360A1 (en) Use of Seaprose to remove bacterial biofilm
EP2440216A1 (en) Use of a composition for the treatment of mucositis
WO2015181551A1 (en) Gold (i)-phosphine compounds as anti-bacterial agents
CA2550983C (en) Enhanced absorption of modified release dosage forms
EP3982975A1 (en) Afabicin for use for treating bacterial infections involving biofilm
US20250090527A1 (en) Wound treatments and compounds
US20140348787A1 (en) Methods and Compositions for Treating Ear Infections
JP2009517374A5 (enExample)
KR102893477B1 (ko) 당뇨병성 족부 감염의 치료제
WO2021202990A2 (en) Methods for the treatment of betacoronavirus infections
EP2203152A1 (en) Mouthwash and method of using same for the treatment of mucositis or stomatitis
US9763934B2 (en) Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast
AU2017258765A1 (en) Methods for the treatment of infection
US20250108027A1 (en) Topical delivery of edta compositions
US10016500B2 (en) Poloxamer-based pharmaceutical compositions for treating wounds
高気圧酸素療法で治療した犬の難治性創傷 A non-healing wound in a dog treated with hyperbaric oxygen therapy
US20240100004A9 (en) Topical compositions and methods of formulating same
Frank et al. Physical Incompatibility of Antibiotics and Antimycotics in Infusion Solutions